Inactive Instrument

EastPharma Ltd.

EAST

US27778Q2049

Eastpharma Ltd Reports Earnings Results for the Full Year Ended December 31, 2018

March 08, 2019 at 06:17 am EST

EastPharma Ltd. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced sales was USD 233.923 million compared to USD 220.429 million a year ago. Net income was USD 29.176 million compared to USD 23.485 million a year ago. Basic earnings per share was USD 0.43 compared to USD 0.35 a year ago.

Latest news about EastPharma Ltd.

Eastpharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Eastpharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-05	CI
Eastpharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-05	CI
Eastpharma Ltd Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-08	CI
Investimentos Corp. acquired 8.2% stake of EastPharma Ltd. from D.E. Shaw Laminar Portfolios, LLC.	18-09-10	CI
EastPharma Ltd. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2018	18-08-13	CI
Eastpharma Announces Audited Earnings Results for the Year Ended December 31, 2017	18-03-09	CI
EastPharma Ltd Reports Earnings Results for the Six Months Ended June 30, 2017	17-08-10	CI
EastPharma Ltd. Reports Revenue Results for the First Quarter Ended March 31, 2017	17-05-03	CI
EastPharma Ltd. Reports Audited Earnings Results for the Year Ended December 31, 2016	17-03-10	CI
EastPharma Ltd. Reports Consolidated Sales Results for the Nine Months Ended September 30, 2016	16-11-03	CI
Eastpharma Ltd. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2016	16-08-10	CI
EastPharma Ltd Announces Sales Results for the First Quarter Ended 31 March 2016	16-05-10	CI
EastPharma Reports Sales Results for the Nine Months of 2015	15-11-05	CI
Eastpharma Ltd. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2015	15-08-12	CI
EastPharma Ltd Announces Earnings Results for the First Quarter of 2015	15-05-06	CI
EastPharma Ltd Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014	15-03-09	CI
Eastpharma Ltd Announces Revenue Results for the Nine Months of 2013	13-11-06	CI
EastPharma Ltd Reports Revenue Results for the First Quarter Ended March 31, 2013	13-05-16	CI
EastPharma Ltd Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2012	13-03-20	CI
EastPharma Ltd Reports Earnings Results for the Nine Months Ended September 30, 2012	12-11-11	CI
EastPharma Ltd Reports Revenue Results for the Nine Months of 2012	12-11-08	CI
EastPharma Ltd Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-08-23	CI
EastPharma Ltd Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2011	12-03-23	CI

Chart EastPharma Ltd.

Duration

Period

More charts

Company Profile

EastPharma Ltd. is the indirect holding company of Deva Holding A.S. (Deva), a pharmaceutical company. The Company operates in the pharmaceutical industry. The Company has three segments: production and sale of human pharmaceuticals (Human Pharma), Veterinary Products and Other. The Human Pharma segment comprises the manufacturing and sale of antibiotic active ingredients and empty ampoules. The Veterinary products segment operates in the sector of veterinary drugs and agrochemicals. Its Other segment includes cologne production and sale. The Company offers medicines indicated for alimentary, metabolism and cardiovascular system and infections. It also conducts, at its microbiology laboratories, tests and research on the adaptation of raw materials, selection of micro-organisms, formulation of culture mediums, and executes various test and research fermentations on pilot fermentators. It has over 150 pharmaceutical molecules in approximately 270 pharmaceutical forms.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals